Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?

Mary E. Rinella*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?'. Together they form a unique fingerprint.